ClinicalTrials.gg
WithdrawnNCT04039477MARINAUpdated Aug 7, 2020

A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP

A Phase 2 interventional study of KZR-616 in Autoimmune Hemolytic Anemia and Immune Thrombocytopenia, sponsored by Kezar Life Sciences, Inc.. Withdrawn at 22 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-07.

Sponsored by Kezar Life Sciences, Inc. · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Clinical trial activity slowdown due to COVID-19 pandemic, high screen fail rate, and lack of enrollment led to the decision to withdraw the MARINA study.
Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 2 randomized, dose-blind, multicenter study designed to evaluate the safety, tolerability, efficacy, Pharmacokinetics (PK), and Pharmacodynamics (PD) of treatment with KZR-616 in patients with active Autoimmune Hemolytic Anemia or Immune Thrombocytopenia.

02

Conditions studied

  • Autoimmune Hemolytic Anemia
  • Immune Thrombocytopenia

Keywords

  • Autoimmune
  • Hemolytic
  • Anemia
  • Autoimmune Hemolytic Anemia
  • AIHA
  • Immune
  • Thrombocytopenia
  • Immune Thrombocytopenia
  • ITP
  • Blood disorders
  • Hematology
03

In context

Anemia, Hemolytic, Autoimmune

103 studies on the registry are indexed under Anemia, Hemolytic, Autoimmune; 39 are open to participants now.

Browse Anemia, Hemolytic, Autoimmune studies →

Lead sponsor

Kezar Life Sciences, Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients must be at least 18 years of age at the time of signing at Screening
  2. (BMI) equal to or greater than 18 kg/m2
  3. Have a documented diagnosis of primary or secondary AIHA, ITP, or primary Evans syndrome
  4. AIHA or ITP disease activity as follows::

    1. ITP: Per central or local laboratory assessments on 2 separate occasions ≥7 days apart during Screening, a mean (PLT) ≤30×109/L with no individual PLT >35×109/L; or for those patients receiving a constant dose of permitted treatments for ITP: a mean PLT \<50×109/L, with no count >55×109/L
    2. AIHA: ≤10 g/dL and presence of any 2 of the following:

    i. Haptoglobin \<lower limit of normal (LLN) ii. Corrected reticulocyte count > (ULN) iii. LDH >ULN iv. Indirect >ULN.

  5. Documented inadequate response on intolerance to ≥1 standard treatment approach for AIHA or ≥2 standard treatment approaches for ITP

Exclusion criteria

Exclusion Criteria:

  1. Systemic Lupus Erythematosus (SLE) with confirmed anti-phospholipid antibody syndrome, the presence of positive lupus anti-coagulant test, moderate-high titer anti-cardiolipin IgG or IgM or moderate-high titer anti-beta2-globuilin IgG or IgM or severe central nervous system involvement
  2. History of coagulopathy, hereditary thrombocytopenia, anemia, or family history of thrombocytopenia
  3. History of primary immunodeficiency
  4. Use of nonpermitted medications within the specified prior to screening
  5. Recent serious or ongoing infection, or risk for serious infection
  6. Any of the following laboratory values at Screening:

    1. Estimated (eGFR) \<45 ml/min
    2. (ANC) \<1.5×109/L (1500/mm3)
    3. Serum (AST), serum alanine transaminase (ALT) or serum alkaline phosphatase >2.5×
    4. Thyroid stimulating hormone if outside of the central laboratory normal range and considered clinically significant
    5. (INR) or activated partial thromboplastin time (aPTT) >1.5×ULN
    6. Immunoglobulin G (IgG) \<500 mg/dL
    7. For ITP patients only: total >1.5×ULN (3×ULN for patients with documented Gilbert's syndrome).
  7. Presence of Class III or IV heart failure, or uncontrolled blood pressure, or prolonged
  8. Major surgery within 12 weeks before Screening or planned during the study period
  9. History of any thrombotic or embolic event within 12 months prior to Screening
  10. Clinical evidence of significant unstable or uncontrolled diseases
  11. Any active or suspected or history of documented malignancy within the last 5 years before Screening, except appropriately excised and cured cervical carcinoma in situ or basal or squamous cell carcinoma of the skin, or non-muscle invasive bladder cancer
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Arm A - KZR-616 30mg

    KZR-616 30mg Subcutaneous (SC) injection weekly for 13 weeks

    Drug: KZR-616

  • Experimental
    Arm B - KZR-616 45mg

    KZR-616 30 mg SC injection weekly for 1 dose then 45mg weekly for 12 weeks.

    Drug: KZR-616

Interventions

  • Patients will receive KZR-616 SC once weekly. Patients assigned to Arm A will receive 30 mg for 13 weeks and patients assigned to Arm B will receive 30 mg for 1 week then 45 mg for 12 weeks

06

What researchers measure

Primary outcomes

  1. Mean change from Baseline to Week 13 in hematologic parameters of interest in evaluable patients (Hgb for AIHA; Platelets [PLT] for ITP)

    Time frame: 13 weeks

Secondary outcomes

  1. Mean change from Baseline to Week 13 in hematologic parameters of interest (Hgb for AIHA; PLT for ITP) in the intent to treat (ITT) population

    Time frame: 13 weeks

  2. Mean change from Baseline over time in hematologic parameters of interest (Hgb for AIHA; PLT for ITP)

    Time frame: Through study completion, up to 25 weeks

  3. Proportion of patients with a response at Week 13

    Time frame: 13 weeks

  4. Proportion of patients over time with a response

    Time frame: Through study completion, up to 25 weeks

  5. Time to response

    Time frame: Through study completion, up to 25 weeks

  6. Proportion of patients over time with loss of response

    Time frame: Through study completion, up to 25 weeks

  7. Proportion of patients over time with sustained response

    Time frame: Through study completion, up to 25 weeks

  8. Mean change from Baseline over time in Hct

    Time frame: Through study completion, up to 25 weeks

  9. Mean change from Baseline over time in Lactate Dehydrogenase (LDH)

    Time frame: Through study completion, up to 25 weeks

  10. Change from Baseline over time in Patient Global Assessment scores

    The PtGA is a visual analog scale (VAS) ranging from 0 to 100. Patients will provide a global rating of their disease, for the day of the visit, in response to the statement "Considering all the ways that your disease affects you, please rate how you are feeling today by clicking or tapping on the line:" using a 100-point VAS where 0 is "very good, no symptoms" and 100 is "very poor, very severe symptoms."

    Time frame: Baseline and every 4 weeks for 25 weeks

  11. For AIHA: Proportion of patients with an Hgb >12 g/dL or 2 g/dL higher than Baseline at W13

    Time frame: 13 weeks

  12. For AIHA: Number of blood transfusions and units of blood administered over time

    Time frame: Through study completion, up to 25 weeks

  13. For ITP: Number of platelet transfusions and units of platelets administered over time

    Time frame: Through study completion, up to 25 weeks

  14. Safety and tolerability of KZR-616 in patients with AIHA or ITP as assessed by monitoring incidence and severity of adverse events (AEs)

    Time frame: Through study completion, up to 25 weeks

  15. Peak Plasma Concentration (Cmax) following KZR-616 injection

    Time frame: Day 1

  16. Peak Plasma Concentration (Cmax) following KZR-616 injection

    Time frame: Day 29

  17. Time to peak plasma concentration (Tmax) following KZR-616 injection

    Time frame: Day 1

  18. Time to peak plasma concentration (Tmax) following KZR-616 injection

    Time frame: Day 29

  19. Area under the plasma concentration versus time curve (AUC) following KZR-616 injection

    Time frame: Day 1

  20. Area under the plasma concentration versus time curve (AUC) following KZR-616 injection

    Time frame: Day 29

  21. Half-life (T1/2) following KZR-616 injection

    Time frame: Day 1

  22. Half-life (T1/2) following KZR-616 injection

    Time frame: Day 29

07

Study locations

22 sites
  • KZR Research Site
    Los Angeles, California 90007, United States
  • KZR Research Site
    San Francisco, California 94143, United States
  • KZR Research Site
    Jacksonville, Florida 32224, United States
  • KZR Research Site
    Miami Lakes, Florida 33014, United States
  • KZR Research Site
    Tampa, Florida 33612, United States
  • KZR Research Site
    Peoria, Illinois 61615, United States
  • KZR Research Site
    Boston, Massachusetts 02114, United States
  • KZR Research Site
    Minneapolis, Minnesota 55454, United States
  • KZR-616 Research Site
    Rochester, Minnesota 55455, United States
  • KZR Research Site
    Morristown, New Jersey 07960, United States
  • KZR Research Site
    Bronx, New York 10467, United States
  • KZR Research Site
    Greenville, North Carolina 27834, United States
  • KZR Research Site
    Cleveland, Ohio 44195, United States
  • KZR Research Site
    Columbus, Ohio 43210, United States
  • KZR Research Site
    Webster, Texas 77598, United States
  • KZR Research Site
    Woolloongabba, Australia
  • KZR Research Site
    Bologna, Italy
  • KZR Research Site
    Genova, Italy
  • KZR Research Site
    Kraków, Poland
  • KZR Research Site
    Poznań, Poland
  • KZR Research Site
    Moscow, Russian Federation
  • KZR Research Site
    Saint Petersburg, Russian Federation
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2020.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2019
First posted
Jul 31, 2019
StartEst.
Jul 2020
Primary completionActual
Aug 5, 2020
CompletionActual
Aug 5, 2020
Last update
Aug 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04039477
Lead sponsor
Kezar Life Sciences, Inc.
Responsible party
Sponsor
First posted
Jul 31, 2019
Start date
Jul 2020 (estimated)
Primary completion
Aug 5, 2020
Completion
Aug 5, 2020
Last update
Aug 7, 2020

Study contacts

Kezar
study director · Kezar Life Sciences, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KZR-616

Start the discussion